11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Abstract The optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the asses...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miao Chen, Wenjia Zhu, Jianhua Du, Chen Yang, Bing Han, Daobin Zhou, Li Huo, Junling Zhuang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1f77fa28b9db4d918610f808c0a0606d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f77fa28b9db4d918610f808c0a0606d
record_format	dspace
spelling	oai:doaj.org-article:1f77fa28b9db4d918610f808c0a0606d2021-11-14T12:21:29Z11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma10.1038/s41598-021-01740-22045-2322https://doaj.org/article/1f77fa28b9db4d918610f808c0a0606d2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01740-2https://doaj.org/toc/2045-2322Abstract The optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the assessment of tumor burden in NDMM. This study evaluated 64 NDMM patients between February 2015 and July 2018. AC-PET and FDG-PET were used to assess myeloma lesions. The clinical data, imaging results, and their correlations were analyzed. Diffuse bone marrow uptake in AC-PET was significantly correlated with biomarkers for tumor burden, including serum hemoglobin (P = 0.020), M protein (P = 0.054), the percentage of bone marrow plasma cells (P < 0.001), and the Durie–Salmon stage of the disease (P = 0.007). The maximum standard uptake value (SUVmax) of focal lesions and high diffuse bone marrow uptake in AC-PET showed stronger correlations with high-risk disease (P = 0.017, P = 0.013) than those in FDG-PET. Moreover, the presence of diffuse bone marrow uptake, more than ten focal lesions, and an SUVmax of focal lesions of > 6.0 in AC-PET, but not in FDG-PET, predicted a higher probability of disease progression and shorter progression-free survival (P < 0.05). AC-PET outperformed FDG-PET in tumor burden evaluation and disease progression prediction in NDMM.Miao ChenWenjia ZhuJianhua DuChen YangBing HanDaobin ZhouLi HuoJunling ZhuangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Miao Chen Wenjia Zhu Jianhua Du Chen Yang Bing Han Daobin Zhou Li Huo Junling Zhuang 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
description	Abstract The optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the assessment of tumor burden in NDMM. This study evaluated 64 NDMM patients between February 2015 and July 2018. AC-PET and FDG-PET were used to assess myeloma lesions. The clinical data, imaging results, and their correlations were analyzed. Diffuse bone marrow uptake in AC-PET was significantly correlated with biomarkers for tumor burden, including serum hemoglobin (P = 0.020), M protein (P = 0.054), the percentage of bone marrow plasma cells (P < 0.001), and the Durie–Salmon stage of the disease (P = 0.007). The maximum standard uptake value (SUVmax) of focal lesions and high diffuse bone marrow uptake in AC-PET showed stronger correlations with high-risk disease (P = 0.017, P = 0.013) than those in FDG-PET. Moreover, the presence of diffuse bone marrow uptake, more than ten focal lesions, and an SUVmax of focal lesions of > 6.0 in AC-PET, but not in FDG-PET, predicted a higher probability of disease progression and shorter progression-free survival (P < 0.05). AC-PET outperformed FDG-PET in tumor burden evaluation and disease progression prediction in NDMM.
format	article
author	Miao Chen Wenjia Zhu Jianhua Du Chen Yang Bing Han Daobin Zhou Li Huo Junling Zhuang
author_facet	Miao Chen Wenjia Zhu Jianhua Du Chen Yang Bing Han Daobin Zhou Li Huo Junling Zhuang
author_sort	Miao Chen
title	11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
title_short	11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
title_full	11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
title_fullStr	11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
title_full_unstemmed	11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
title_sort	11c-acetate positron emission tomography is more precise than 18f-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1f77fa28b9db4d918610f808c0a0606d
work_keys_str_mv	AT miaochen 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT wenjiazhu 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT jianhuadu 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT chenyang 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT binghan 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT daobinzhou 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT lihuo 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma AT junlingzhuang 11cacetatepositronemissiontomographyismoreprecisethan18ffluorodeoxyglucosepositronemissiontomographyinevaluatingtumorburdenandpredictingdiseaseriskofmultiplemyeloma
_version_	1718429215395676160

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Ejemplares similares